Screener
Cullinan Therapeutics, Inc. CGEM Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $44.44M-27.2% | $42.12M+1.6% | $42.95M+6.1% | $41.97M+18.2% | $61.03M+68.3% | ||
| $12.82M-13.2% | $11.57M-14.5% | $12.31M-15.4% | $13.63M+2.1% | $14.77M+7.3% | ||
| $57.25M-24.5% | $53.7M-2.4% | $55.26M+0.4% | $55.6M+13.8% | $75.8M+51.5% | ||
| -$57.25M+24.5% | -$53.7M+2.4% | -$55.26M-0.4% | -$55.6M-13.8% | -$75.8M-51.5% | ||
| -$98K+45.9% | -$62K+27.1% | -$69K— | -$108K-21.3% | -$181K-151% | ||
| -$53.7M+23.3% | -$49.66M-2.4% | -$50.71M-6.4% | -$50.61M-24.8% | -$70.06M-66.7% | ||
| —— | —— | —— | —— | —— | ||
| -$57.18M+24.5% | -$53.62M+2.4% | -$55.18M-0.4% | -$55.52M-13.8% | -$75.72M-51.6% | ||
| -$57.25M+24.5% | -$53.7M+2.4% | -$55.26M-0.4% | -$55.6M-13.8% | -$75.8M-51.5% |
FAQ
- Is Cullinan Therapeutics, Inc. profitable?
- Cullinan Therapeutics, Inc. is not currently profitable: it reported a net loss of $204.7M over the trailing twelve months, a -346.1% net margin.
- Where does Cullinan Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Cullinan Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.